Combined Aerobic Exercise and Cognitive Training in Seniors With Genetic Susceptibility for Alzheimer's Disease

Sponsor
Xuanwu Hospital, Beijing (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05163067
Collaborator
(none)
200
1
2
120
1.7

Study Details

Study Description

Brief Summary

The study aims to investigate the effect of a long-term combined aerobic exercise and cognitive training program on cognitive function, daily function, psychosocial status, and neural plasticity in seniors with genetic susceptibility for Alzheimer's Disease.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Combined aerobic exercise and cognitive training program
N/A

Detailed Description

Alzheimer's disease (AD) is the most common type of dementia and the leading cause of disability in people older than 65 years worldwide. However, there is no effective disease-modifying therapy currently. Therefore, improvement of cognitive function in people at risk and, potentially, prevention of cognitive decline has been gaining attraction.

Our previous research reported a model of a combination single nucleotide polymorphism (SNP) (rs3777215, rs234434, rs71352238, and rs4420638) can predict AD onset with high performance, which is useful to identify people at risk for AD and thus allows for timely treatment and prevention.

Both aerobic exercise and cognitive training have been demonstrated beneficial effects on cognition in subjects with AD and healthy populations. Moreover, the synergistic effects of the combination have been proven recently. However, the effect of combined aerobic exercise and cognitive training on seniors with genetic susceptibility for AD remains to be elucidated. Herein, this study aims to

  1. assess the effects of long-term combined aerobic exercise and cognitive training on cognitive function, daily function, psychosocial status, and neural plasticity in seniors with single nucleotide polymorphism of rs3777215, rs234434, rs71352238, and rs4420638.

  2. confirm the predictive value of the SNP model for AD in a longitudinal setting.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Combined Aerobic Exercise and Cognitive Training for Alzheimer's Disease Prevention in Seniors With Genetic Susceptibility Estimated by Polygenic Risk Models: Cognition and Neural Plasticity Effects
Anticipated Study Start Date :
Jun 1, 2023
Anticipated Primary Completion Date :
Jun 1, 2033
Anticipated Study Completion Date :
Jun 1, 2033

Arms and Interventions

Arm Intervention/Treatment
Experimental: Combined aerobic exercise and cognitive training program

Behavioral: Combined aerobic exercise and cognitive training program
Participants will take part in a combined aerobic exercise and cognitive training program. The program will include moderate cycling exercise and cognitive game resolving at the same time. The tasks will be instructed and supervised by a fitness expert and a trained clinical neuropsychologist.

No Intervention: Standard health counseling at baseline

Outcome Measures

Primary Outcome Measures

  1. Change in cognitive function over time as assessed by the Montreal Cognitive Assessment (MoCA) [baseline time, year 1, year 3, year 5, year 7]

    MoCA will be performed to evaluate the cognition of participants at the enrollment and year 1, year 3, year 5, year 7. The score ranges from 0 to 30, with higher values indicating better cognition.

  2. Change in cognitive function over time as assessed by Mini Mental State Examination (MMSE) [baseline time, year 1, year 3, year 5, year 7]

    MMSE will be performed to evaluate the cognition of participants at the enrollment and year 1, year 3, year 5, year 7. The score ranges from 0 to 30, with higher values indicating better cognition.

  3. Change in cognitive function over time as assessed by Clinical Dementia Rating (CDR) [baseline time, year 1, year 3, year 5, year 7]

    CDR will be performed to evaluate the cognition of participants at the enrollment and year 1, year 3, year 5, year 7. The score ranges from 0 to 18, with higher values indicating worse cognition.

  4. Change in cognitive function over time as assessed by Verbal Fluency Test [baseline time, year 1, year 3, year 5, year 7]

    Verbal Fluency Test will be performed to evaluate the semantic memory function of participants at the enrollment and year 1, year 3, year 5, year 7. Participants are asked to produce as many animals as possible within 1 minute. The score is the number of animals, with higher scores indicating better cognition.

  5. Change in cognitive function over time as assessed by Digit Span Test-Forward and Backward [baseline time, year 1, year 3, year 5, year 7]

    Digit Span Tests will be performed to evaluate the working memory of participants at the enrollment and year 1, year 3, year 5, year 7. The total scores are twelve for each test, with higher values indicating better cognition.

  6. Change in cognitive function over time as assessed by Trail-Making Test Parts A and B (TMT-A and TMT-B) [baseline time, year 1, year 3, year 5, year 7]

    TMT-A and TMT-B will be performed to evaluate the executive function of participants at the enrollment and year 1, year 3, year 5, year 7. Scoring is based on time taken to complete the test (e.g., 35 seconds yielding a score of 35), with lower scores indicating better cognition.

  7. Change in cognitive function over time as assessed by Boston Naming Test (BNT) [baseline time, year 1, year 3, year 5, year 7]

    BNT will be performed to evaluate the language function of participants at the enrollment and year 1, year 3, year 5, year 7. The score ranges from 0 to 30, with higher values indicating better cognition.

  8. Change in cognitive function over time as assessed by California Verbal Learning Test (CVLT) [baseline time, year 1, year 3, year 5, year 7]

    CVLT will be performed to evaluate the memory function of participants at the enrollment and year 1, year 3, year 5, year 7. Participants are asked to finish immediate recall, delayed recall, and delayed recognition tasks in the test, with higher scores indicating better cognition.

  9. Change in cognitive function over time as assessed by the Rey-Osterrieth Complex Figure Test (ROCF) [baseline time, year 1, year 3, year 5, year 7]

    ROCF will be performed to evaluate the visuospatial function and other cognition domains of participants at the enrollment and year 1, year 3, year 5, year 7. Participants are asked to produce a complicated line drawing, with higher scores indicating better cognition.

  10. The area under curve of the SNP model (rs3777215, rs234434, rs71352238 and rs4420638) for the accurate diagnosis of AD [up to 7 years]

    The area under curve is used to show the ability of the SNP model (rs3777215, rs234434, rs71352238 and rs4420638) to diagnose AD. The value of area under curve is higher, then the ability of the SNP model to diagnose AD is stronger.

Secondary Outcome Measures

  1. Change in whole brain volume as accessed by brain MRI [baseline time, year 1, year 3, year 5, year 7]

    Brain MRI will be performed to evaluate the whole brain volume of participants at the enrollment and year 1, year 3, year 5, year 7. Whole brain volume is measured in mL and determined by Freesurfer analysis. There is no defined maximum. Zero is the theoretical minimum. Greater number indicates larger brain volume.

  2. Change in daily function over time as assessed by Activities of daily living (ADL) [baseline time, year 1, year 3, year 5, year 7]

    ADL will be performed to evaluate the daily function of participants at the enrollment and year 1, year 3, year 5, year 7. The score ranges from 14 to 64, with lower values indicating better function.

  3. Change in anxiety over time as assessed by Hamilton Anxiety Rating Scale (HAMA) [baseline time, year 1, year 3, year 5, year 7]

    HAMA will be performed to evaluate the daily function of participants at the enrollment and year 1, year 3, year 5, year 7. The score ranges from 0 to 64, with higher values indicating more severe anxiety.

  4. Change in depression over time as assessed by Hamilton Depression Scale (HAMD) [baseline time, year 1, year 3, year 5, year 7]

    HAMD will be performed to evaluate the daily function of participants at the enrollment and year 1, year 3, year 5, year 7. The score ranges from 0 to 96, with higher values indicating more severe depression.

  5. Change in neuropsychiatric symptoms over time as assessed by Neuropsychiatric Inventory Questionnaire (NPI-Q) [baseline time, year 1, year 3, year 5, year 7]

    NPI-Q will be performed to evaluate the daily function of participants at the enrollment and year 1, year 3, year 5, year 7. The score ranges from 0 to 144, with higher values indicating more severe neuropsychiatric symptoms.

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Mandarin-speaking subjects.

  • Not clinically demented.

  • Meeting the cutoff values of MMSE and CDR.

  • With positive variation of rs3777215, rs234434, rs71352238, and rs4420638.

Exclusion Criteria:
  • Had major neurologic diagnosis (e.g., Parkinson's disease, stroke, encephalitis, and epilepsy) or other condition that might impair cognition or confound assessments.

  • Had a history of psychotic episodes or had major depression (Hamilton Depression Rating Scale score > 24 points).

  • Had severe systemic diseases, such as tumors, cardiovascular or orthopedic disorder that can affect the ability to perform the proposed intervention tasks.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Xuanwu Hospital Beijing China

Sponsors and Collaborators

  • Xuanwu Hospital, Beijing

Investigators

  • Principal Investigator: Longfei Jia, MD,PhD, Xuanwu Hospital, Beijing

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Xuanwu Hospital, Beijing
ClinicalTrials.gov Identifier:
NCT05163067
Other Study ID Numbers:
  • ICND20210820
First Posted:
Dec 20, 2021
Last Update Posted:
Dec 20, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Xuanwu Hospital, Beijing
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 20, 2021